A case of erythema multiforme drug eruption associated with erythrodermic psoriasis induced by sofosbuvir and daclatasvir.

WHAT IS KNOWN AND THE

OBJECTIVE

Sofosbuvir (SOF) and daclatasvir (DCV) have revolutionized the treatment of hepatitis C virus and now represent the preferred therapy for this disease. Limited data are available on the dermatological side effects resulting from co-administration of SOF and DCV.

CASE DESCRIPTION: We report a case of an erythema multiforme drug eruption associated with erythrodermic psoriasis induced by SOF and DCV. After ceasing treatment, the skin condition significantly improved.

WHAT IS NEW AND

CONCLUSION

We should pay attention to adverse skin reactions resulting from SOF and DCV, especially if the patient has a pre-existing dermatosis.